BridgeBio Enters Collaborations with Three Academic Research Institutions
July 8, 2021
BridgeBio Pharma entered three new academic collaborations—with MUSC Foundation for Research Development, Stanford University, and the University of Pittsburgh—to translate discoveries into potential therapies for patients with genetic diseases and genetically driven cancers.
“The chance to partner with exceptional researchers at the Medical University of South Carolina, Stanford University and University of Pittsburgh is a privilege, and we believe will help us advance our mission to discover, create, test and deliver life-changing medicines for patients in need as rapidly as possible,” said BridgeBio founder and CEO Neil Kumar.
MUSC Foundation for Research Development provides technology transfer services to Medical University of South Carolina (MUSC), which is a patient-centric research institution with several hospitals in South Carolina and is considered the state’s top healthcare provider. MUSC’s research will allow for early identification of research programs with a strong potential to be beneficial for patients. Through this partnership, BridgeBio may sponsor research programs and support the development of identified programs toward potential clinical investigation through its licensing and affiliate development model.
The collaboration between BridgeBio and Stanford University is focused on unlocking new discoveries and working to provide valuable treatment options to patients with unmet needs. BridgeBio will work with Stanford researchers to identify new potential therapies with the possibility of BridgeBio providing support for these programs and potentially advancing them into clinical trials and commercializing new medicines.
The University of Pittsburgh (Pitt) is a leading research institution with broad strengths spanning basic research to clinical translation. BridgeBio intends to collaborate with Pitt to identify and support the development of potential novel therapies for patients with genetic diseases and cancers with clear genetic drivers.
Since its founding in 2015 to discover, create, test, and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, BridgeBio has worked with 23 leading institutions throughout the country that are focused on providing treatment options to patients as quickly and safely as possible.
Author: Rare Daily Staff
Sign up for updates straight to your inbox.